Abstract: The invention provides a composition for use as a delivery vehicle comprising at least one thermo-responsive polymer (polymer A) and at least one ion-sensitive polymer (polymer B) in a liquid formulation. Polymer A is preferably a polyoxyethylene-polyoxypropylene block copolymer or a cellulose derivative. Polymer B a polysaccharide. The composition can include an active substance for delivery or can be used as a delivery vehicle for a substance added at the time of administration such as mesenchymal stem cells.

Abstract: Disclosed are a new composition of lipoamino acids and alkanediols, a process for the preparation thereof, and a cosmetic or pharmaceutical composition resulting therefrom.

Abstract: The present disclosure provides colorant compounds and methods of isolation of the colorant compounds derived from a reaction of genipin and an amine. The colorant compositions comprise purified compounds (e.g., a purified polymer or a purified dimer) obtained from multiple fractioning by chromatography of the reaction resulting material. The purified polymer or dimer can be used as a colorant by itself or in combination with another colorant for imparting color to a food, a drug, a cosmetic, a medical device, and textile products.

Abstract: Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for a variety of applications, including, but not limited to, drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells and capsules with a functional polymer dispersion. The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with controlled release properties. The present disclosure also relates to aqueous compositions for use in the manufacture of capsule shells and capsules endowed with moisture barrier properties. The present disclosure also relates to methods of manufacturing the capsule shell and capsules, and to capsule shells and capsules obtained therewith.

Abstract: Compositions comprising a polymer-based macroscopically homogeneous polymer alloy comprising a plurality of microcrystalline components dispersed within an amorphous component, which is biocompatible, bioerodable, substantially non-toxic, and excretable, or metabolized when introduced into a mammalian body. In preferred embodiments, malleable molded devices such as implants, films, drug delivery systems and the like, are comprised of the compositions. Methods of making such compositions by controlled cooling of the molten alloy are also described.

Abstract: A synthetic construct suitable for implantation into a biological organism that includes at least one polymer scaffold; wherein the at least one polymer scaffold includes at least one layer of polymer fibers that have been deposited by electrospinning; wherein the orientation of the fibers in the at least one polymer scaffold relative to one another is generally parallel, random, or both; and wherein the at least one polymer scaffold has been adapted to function as at least one of a substantially two-dimensional implantable structure and a substantially three-dimensional implantable tubular structure.

Abstract: Nanocarriers are synthesized with polymers that respond to lower pH and/or ROS by being degraded. The compositions may be utilized to selectively deliver payloads within patients by responding to lower pH and/or ROS at localities within the patient. The present invention also features methods of synthesizing nanocarriers that are degraded by lower pH and/or ROS.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: A water-swellable linear polymer is made by reacting together a polyethylene oxide of number average molecular weight less than 4,000, an aliphatic diol, and a difunctional diisocyanate. Controlled release composition comprises the polymer together with an active agent. The polymer is able to take up pharmaceutically active agents of molecular weight 200 to 20,000.

Abstract: Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.

Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Abstract: The present invention provides new classes of phenolic compounds derived from hydroxyacids and tyrosol or tyrosol analogues, useful as monomers for preparation of biocompatible polymers, and the biocompatible polymers prepared from these monomeric hydroxyacid-phenolic compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric hydroxyacid-phenolic compounds and biocompatible polymers.

Abstract: Bioactive liquid formulations are formed of combinations of absorbable, segmented aliphatic polyurethane compositions and liquid polyether for use as vehicles for the controlled release of at least one active agent for the conventional and unconventional treatment of different forms of cancer and the management of at least one type of bacterial, fungal, and viral infection.

Abstract: In one aspect, the present disclosure pertains to lubricous coating compositions that comprise (a) a higher molecular weight polyvinylpyrrolidone, (b) a lower molecular weight polyvinylpyrrolidone, and (c) a polyfunctional unsaturated crosslinking agent. In some embodiments, such lubricous coating compositions are present in crosslinked form on the surface of a medical article. In some embodiments, the lubricous coating compositions further comprise a solvent, in which case such compositions may be, for example, applied to a substrate in the form of a layer and subsequently crosslinked, thereby forming a lubricious coating on the substrate. In another aspect, the present disclosure is directed to methods for forming various medical articles.

Abstract: The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric reflux and/or for treating erectile dysfunction and/or for treating vocal cords. The gel may also be used for cosmetic applications.

Abstract: The present invention relates to the preparation of poly(amino oxalate) (PAOX) using oxalyl chloride, 1,4-cyclohexanedimethanol, and piperazinediethanol, the preparation of biodegradable polymer particles using the PAOX, and the use of PAOX particles as a drug delivery vehicle. The PAOX according to the present invention is a polymer that has three characteristics of biodegradability, biocompatibility, and cationic properties at the same time with appropriate hydrophobicity and thus can be prepared as particles that allow rapid drug release. Moreover, the particles improve the delivery efficiency of a drug into cells and thus can be efficiently used as a drug delivery vehicle for the treatment of acute inflammatory diseases such as acute liver failure and acute lung injury.

Abstract: The present invention relates to development of efficacious pharmaceutical implant compositions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000.

Abstract: The present disclosure provides colorant compounds and methods of isolation of the colorant compounds derived from a reaction of genipin and an amine. The colorant compositions comprise purified compounds (e.g., a purified polymer or a purified dimer) obtained from multiple fractioning by chromatography of the reaction resulting material. The purified polymer or dimer can be used as a colorant by itself or in combination with another colorant for imparting color to a food, a drug, a cosmetic, a medical device, and textile products.

Abstract: Poly(amine-co-ester) polymers, methods of forming active agent-load nanoparticles therefrom, and methods of using the nanoparticles for drug delivery are disclosed. The nanoparticles can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticles are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the nanoparticles are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition.

Abstract: Embodiments include a vehicle for delivery of nitric oxide comprising: a collection of micelles having an internal micelle core that comprises a polymer with N-diazeniumdiolate comprising NO complexed with secondary amines of the polymer. Embodiments include a method of making a nitric oxide vehicle comprising dissolving a polymer that comprises secondary amines in an aqueous solution and combining the polymer with nitric oxide in the solution to form a N-diazeniumdiolate comprising the nitric oxide complexed with the secondary amines, with the formation of the N-diazeniumdiolate causing the polymer to be at least partially insoluble in the solution and to form a collection of micelles that have an internal core that comprises N-diazeniumdiolate.

Abstract: Implantable devices formed of or coated with a material that includes an amorphous poly(D,L-lactide) formed of a starting material such as meso-D,L-lactide are provided. The implantable device can be used for the treatment, mitigation, prevention, or inhibition of a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

Abstract: This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.

Abstract: The present invention relates to topical antibacterial compositions. The compositions comprise an antibacterial agent such as mupirocin, water, a polymer and a volatile solvent present in an amount of less than about 40%. The invention also relates to methods of treatment by administering the compositions to a patient in need thereof, and to the use of such compositions in the treatment of bacterial conditions.

Abstract: The present invention relates to water soluble and completely absorbable and/or physiologically degradable hemostatic compositions having a wax or wax-like base effective for use in tamponade hemostasis of bone or cartilage.

Abstract: The present invention discloses polymeric materials that incorporate a modified quinone moiety, either to cross-link the polymer or as a monomeric unit of the polymer. These polymeric materials can be efficiently degraded through electrochemical reduction of the quinone leading to rapid hydrolysis of the pendant chemical groups and degradation of the polymer. Quinone-containing compositions and methods of producing electrochemically degradable polymers are disclosed. The methods and compositions of the present invention can be used in a wide variety of applications, including, but not limited to, drug delivery, tissue regeneration, biomedical implants, and electronic systems.

Abstract: Systems and method are disclosed for forming a biocompatible cross-linked polymer having an interpenetrating polymer network (IPN) by cross-linking a heteropolysaccharide to form a single cross-linked material; and performing one or more additional cross-linkings on the single cross-linked material to form a multiple cross-linked material, wherein the multiple cross-linked material has one or more IPN regions resisting biodegradation in a human body than the single cross-linked material and one or more single cross-linked extensions radiating out from the IPN, wherein the combination of the IPN and the extension provide biodegradation resistance, soft touch feeling, and ease of insertion into the human body.

Abstract: The invention relates to polymers, such as aliphatic polyesters, with grafted zwitterions. More particularly, the invention relates to polyester-graft-phosphorylcholine polymers prepared by ring-opening polymerization and click chemistry, compositions and products comprising same, and related methods and uses, for example, in drug delivery.

Abstract: The present invention provides gradient porous scaffolds for bone regeneration and osteochondral defect repair, methods for making such gradient porous scaffolds, and methods for using the gradient porous scaffolds.

Abstract: The present invention relates to a fiber comprising a biodegradable polymer which undergoes dimensional change upon injection in the human or animal body wherein the dimensional change is a reduction of the surface area to volume ratio of a factor 2 to 10. The fiber is sized for injection via a pharmaceutical syringe needle having a bore of at least 25 Gauge. The biodegradable polymer is an amorphous biodegradable polymer selected from the group of poly-hexamethylene carbonates or polyesteramides. The amorphous biodegradable polymer is a preferably a polyesteramide comprising alpha-amino acids, diols and dicarboxylic acids as building blocks. The invention further relates to the use of the fiber for the manufacturing of a medicament for the treatment of ophthalmic diseases. The invention also relates to a process for the manufacturing of the fiber comprising the following process steps; a. extruding a biodegradable polymer into a fiber fitting in a needle of at least 25 Gauge b.

Abstract: A bioresorbable porous film, including a blend mixture of polylactic acid and at least two kinds of polyethylene glycol, wherein the at least two kinds of polyethylene glycol include a first polyethylene glycol, which is in a solid form under ambient temperature and atmospheric pressure, and a second polyethylene glycol, which is in a liquid form under ambient temperature and atmospheric pressure is provided. The film has a porosity of 10%-90%.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: Long acting injectable analgesic formulations and methods for providing long lasting pain relief in animals are disclosed.

Abstract: Described are drug delivery systems incorporating electrospun fibers that comprise and deliver physicochemically diverse drug compounds. Such fibers provide significant advantages in drug agent release, such as adaptability for solid dosage delivery to mucosal tissues. This is in addition to allowing for controlled drug release. Systems and methods for large-scale electrospinning productivity are described, including novel microarchitectures allowing for variable pharmacokinetics in drug release.

Abstract: The present invention relates to novel biodegradable materials based on modified polyamino acids that are useful in particular in the vectorization of active principle(s) (APs). The invention is also directed to novel pharmaceutical, cosmetic, health-food or plant-protection compositions based on these polyamino acids. The aim of the invention is to provide a novel polymeric starting material which can be used for AP vectorization and which satisfy all the requirements: biocompatibility, biodegradability, ability to easily associate with or dissolve numerous active principles and to release these active principles in vivo. This goal is achieved by the present invention, which relates to novel polyglutamates modified by cationic groups, which, if they can be deprotonated, exhibit a pKa equal to or greater than 7, and by hydrophobic groups comprising from 8 to 30 carbon atoms.

Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Abstract: The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient. Most preferably, the dosage form includes verapamil. These formulations have reduced potential for abuse. In another formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding.

Abstract: The present invention relates inter alia to the use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolution kinetics (dissolution) and/or the water loading of tablets.

Abstract: Poly(?-amino esters) prepared from the conjugate addition of bis(secondary amines) or primary amines to a bis(acrylate ester) are described. Methods of preparing these polymers from commercially available starting materials are also provided. These tertiary amine-containing polymers are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the poly(amine) nature of these polymers, they are particularly suited for the delivery of polynucleotides. Nanoparticles containing polymer/polynucleotide complexes have been prepared. The inventive polymers may also be used to encapsulate other agents to be delivered. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

Abstract: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (R; A), (ii) at least one reverse-flight section (D), and (iii) a discharging section (E), wherein the processing elements defining the reverse-flight section (R; D) comprise at least one reverse-flight element (14) which is based on a screw-type element having a conveying direction being opposite to the general conveying direction of the extruder.

Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.

Abstract: Novel bioabsorbable polymeric blends are disclosed. The blends have a first component that is a polylactide polymers or a copolymer of lactide and glycolide and a second component that is poly(p-dioxanone) polymer. The novel polymeric blends provide medical devices having dimensional stability. Also disclosed are novel bioabsorbable medical devices made from these novel polymer blends, as well as novel methods of manufacture.

Abstract: The invention provides moldable drug delivery carriers made up of a suspension of a solid phase and an organic liquid phase for the sustained release of a therapeutic agent. The invention also provides multiphase drug delivery systems made up of a granular hydrophobic solid phase, an organic liquid phase and a hydrogel, for sustained drug delivery at varying rates over the life of the composition.

Abstract: A formulation containing a biologically active compound having a chemical structure with hydrogen bonding sites, a first biocompatible, hydrolytically degrading polycarbonate with hydrogen bonding sites and tyrosine-derived diphenol monomer units, and a second biocompatible hydrolytically degrading polymer that is less hydrophobic than the polycarbonate, wherein the second polymer degrades hydrolytically to form acidic degradation products that promote the release of the active compound. Methods for active compound delivery are also disclosed.

Abstract: A block or graft copolymer includes a first block, and a second block different from the first block, wherein the first block is a poly(lactide-glycolide) copolymer. The polymers may be formulated in compositions with drug components for use in coating medical devices such as stents. Different blocks of the block or graft copolymer degrade in the body at different rates. The drug release profile from the coating is a combination the individual release rates of the different blocks and so can be controlled by controlling the selection and relative amounts of the respective blocks.

Abstract: The present application discloses a sustained release composition in pellet form, wherein the core of the pellet comprises: (a) a therapeutically effective amount of a medicament; (b) 0.5 to 50% by weight of a water-soluble polymer; and (c) 1 to 25% by weight of a water-insoluble polymer applied as an aqueous latex dispersion and subsequently the water is removed, wherein the sum of the percentages of the medicament, the water-insoluble polymer and the water-soluble polymer is equal to or less than 100%. It also discloses methods of making this composition.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agent compositions and formulations administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: The invention discloses composition of oxidized conducting polymer and micelle assembly for site specific delivery of guest molecule. This delivery is achieved by by polyvalent interaction between micelle assemblies and delocalized charges of polymer to trigger the disassembly. The invention further discloses the process of preparation of composition of oxidized conducting polymer and micelle assembly for site specific delivery of guest molecule.

Abstract: Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.

Abstract: The use of copolymers obtained by free-radical polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam, ii) 10 to 50% by weight of vinyl acetate, and iii) 10 to 50% by weight of a polyether, with the proviso that the total of components i), ii) and iii) equals 100% by weight, as solubilizers for slightly water-soluble substances.